All Episodes

Ep. 117 - C-Path's Klaus Romero on moving genetic medicines beyond one patient

Ep. 116 - Ovid's Jeremy Levin on biotech in the balance

Ep. 115 - Initiate's Owens on what it takes to be AI-native

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy